Literature DB >> 9010024

Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer.

A Pifarré1, R Rosell, M Monzó, J M De Anta, I Moreno, J J Sánchez, A Ariza, J L Mate, E Martińez, M Sánchez.   

Abstract

As chromosomes 2p and 3p are frequent targets for genomic instability in lung cancer, we have addressed whether alterations of simple (CA)n DNA repeats occur in non-small-cell lung cancer (NSCLC) at early stages. We have analysed by polymerase chain reaction (PCR) assay replication errors (RER) and loss of heterozygosity (LOH) at microsatellites mapped on chromosomes 2p and 3p in 64 paired tumour-normal DNA samples from consecutively resected stage I, II or IIIA NSCLC. DNA samples were also examined for K-ras and p53 gene mutations by PCR-single-stranded conformational polymorphism (PCR-SSCP) analysis and cyclic sequencing, as well as their relationship with clinical outcome. Forty-two of the 64 (66%) NSCLC patients showed RER at single or multiple loci. LOH was detected in 23 tumours (36%). Among patients with stage I disease, the 5-year survival rate was 80% in those whose tumours had no evidence of RER and 26% in those with RER (P = 0.005). No correlation was established between RER phenotype and LOH, K-ras or p53 mutations. RER remained a strong predictive factor (hazard ratio for death, 2.89; 95% confidence interval, 2.23-3.79; P = 0.002) after adjustment for all other evaluated factors, including p53, K-ras, LOH, histological type, tumour differentiation and TNM stage, suggesting that microsatellite instability on chromosomes 2p and 3p may play a role in NSCLC progression through a different pathway from the traditional tumour mechanisms of oncogene activation and/or tumour-suppressor gene inactivation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010024      PMCID: PMC2063273          DOI: 10.1038/bjc.1997.31

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Three distinct regions involved in 3p deletion in human lung cancer.

Authors:  K Hibi; T Takahashi; K Yamakawa; R Ueda; Y Sekido; Y Ariyoshi; M Suyama; H Takagi; Y Nakamura; T Takahashi
Journal:  Oncogene       Date:  1992-03       Impact factor: 9.867

Review 2.  A new international staging system for lung cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1986-04       Impact factor: 9.410

3.  A hereditary genetic marker closely associated with microsatellite instability in lung cancer.

Authors:  D Ryberg; B A Lindstedt; S Zienolddiny; A Haugen
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

4.  Microsatellite instability and other molecular abnormalities in non-small cell lung cancer.

Authors:  K M Fong; P V Zimmerman; P J Smith
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

5.  Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction.

Authors:  M A Peinado; S Malkhosyan; A Velazquez; M Perucho
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

6.  Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer.

Authors:  A Hemminki; P Peltomäki; J P Mecklin; H Järvinen; R Salovaara; M Nyström-Lahti; A de la Chapelle; L A Aaltonen
Journal:  Nat Genet       Date:  1994-12       Impact factor: 38.330

7.  Microsatellite alterations as clonal markers for the detection of human cancer.

Authors:  L Mao; D J Lee; M S Tockman; Y S Erozan; F Askin; D Sidransky
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett's-associated esophageal adenocarcinoma.

Authors:  C M Gleeson; J M Sloan; J A McGuigan; A J Ritchie; J L Weber; S E Russell
Journal:  Cancer Res       Date:  1996-01-15       Impact factor: 12.701

9.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer.

Authors:  Y Horio; T Takahashi; T Kuroishi; K Hibi; M Suyama; T Niimi; K Shimokata; K Yamakawa; Y Nakamura; R Ueda
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

10.  Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis.

Authors:  T A Brentnall; R Chen; J G Lee; M B Kimmey; M P Bronner; R C Haggitt; K V Kowdley; L M Hecker; D R Byrd
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

View more
  5 in total

1.  Arsenic Inhibits DNA Mismatch Repair by Promoting EGFR Expression and PCNA Phosphorylation.

Authors:  Dan Tong; Janice Ortega; Christine Kim; Jian Huang; Liya Gu; Guo-Min Li
Journal:  J Biol Chem       Date:  2015-04-23       Impact factor: 5.157

2.  Analysis of microsatellite mutations in buccal cells from a case-control study for lung cancer.

Authors:  Jessica L Baumann; Ming Li; Aslak Poulsen; Nicholson S Chadwick; Qiuyin Cai; Christine H Chung; Yu Shyr; Jørgen H Olsen; Wei Zheng; Robbert J C Slebos
Journal:  Cancer Epidemiol       Date:  2011-11-06       Impact factor: 2.984

3.  Investigation of c-myc and p53 gene alterations in the tumor and surgical borderline tissues of NSCLC and effects on clinicopathologic behavior: by the FISH technique.

Authors:  T Yakut; U Egeli; C Gebitekin
Journal:  Lung       Date:  2003       Impact factor: 2.584

Review 4.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

Authors:  C Mascaux; N Iannino; B Martin; M Paesmans; T Berghmans; M Dusart; A Haller; P Lothaire; A-P Meert; S Noel; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

5.  Runs of homozygosity associate with decreased risks of lung cancer in never-smoking East Asian females.

Authors:  Yi-Xiao Chen; Yan Guo; Shan-Shan Dong; Xiao-Feng Chen; Jia-Bin Chen; Yu-Jie Zhang; Shi Yao; Hlaing Nwe Thynn; Liqiang Zhi; Tie-Lin Yang
Journal:  J Cancer       Date:  2018-10-05       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.